FGF2 and nasopharyngeal carcinoma: Given the fact that FGF-2 signaling inhibition significantly promoted the therapeutic effects of AAD in NPC, we hypothesized that combination therapy targeting both FGF-2 and VEGF signaling may overcome the AAD resistance in NPC.